Abstract
Prevalence of metabolic syndrome (MS) is rising as a consequence of obesity epidemic. The components of MS are related to each other and together with hypertension represent a hight risk for cardiovascular diseases.
Antihypertensive drugs with favorable metabolic efect should be chosen for treatment of hypertension in MS. Treatment of hypertension in patients with MS follows the same rules as in diabetics.
Pharmacotherapy is indicated when blood pressure values reach >= 140/90 mmHg. In diabetics, the exact target for blood pressure has not been determined yet.
A combination therapy is usually necessary to achieve a decrease of blood pressure under 140/90 mmHg in patients with diabetes and ACE-I/sartans medication should be prefered. Finally, there is a prognostic relevance to involve the rest components of MS pharmacologically.